In the rapidly evolving landscape of diabetes research, scientists are continuously exploring novel therapeutic strategies to mitigate the devastating complications associated with this chronic disease. Among these, cognitive dysfunction remains a pressing concern, particularly in patients suffering from type 2 diabetes mellitus (T2DM). Recent groundbreaking research has shed light on an innovative combinational treatment approach involving the use of purslane ethanolic extract alongside metformin, revealing promising results in the attenuation of cognitive impairments in diabetic models. This study, anchored in rigorous experimental methods, provides compelling evidence that targeting oxidative stress, neuroinflammation, and neurotransmitter dysregulation can effectively counteract the cognitive decline typically observed in diabetes.
The study utilized high-fat diet and streptozotocin (HFD/STZ)-induced diabetic rats, a well-established animal model that closely mimics the pathophysiological conditions of T2DM in humans, including metabolic disturbances and cognitive deficits. This model is crucial for understanding the intricate relationship between diabetes and neurodegeneration. By administering a combined regimen of purslane ethanolic extract and metformin, the researchers observed marked improvements in the cognitive functions of these rats, assessed through a variety of behavioral and biochemical assays. This dual treatment strategy signifies a promising horizon for addressing not only glycemic control but also the neurological impairments associated with diabetes.
Purslane (Portulaca oleracea), a succulent plant commonly used in traditional medicine, is rich in bioactive compounds such as flavonoids, alkaloids, omega-3 fatty acids, and vitamins. The ethanolic extract of purslane has long been recognized for its potent antioxidant and anti-inflammatory properties. In this study, its synergistic effect with metformin, a widely prescribed antidiabetic drug, was critically examined to assess whether it could offer neuroprotective benefits beyond glycemic regulation. The ethnopharmacological relevance of purslane is underscored by its capacity to modulate oxidative stress pathways, which are notably exacerbated in diabetic neuropathies.
Oxidative stress is a fundamental mechanism contributing to the neuronal damage observed in diabetes-induced cognitive dysfunction. Elevated blood glucose levels lead to increased production of reactive oxygen species (ROS) and reactive nitrogen species, overwhelming the endogenous antioxidant defenses and causing cellular injury. The administration of purslane extract in conjunction with metformin was demonstrated to significantly reduce markers of oxidative damage in the brain tissue of diabetic rats. This reduction correlated strongly with the preservation of neuronal integrity and function, highlighting the critical role of antioxidative intervention in managing diabetes-related neurodegeneration.
Neuroinflammation, characterized by the activation of glial cells and the release of pro-inflammatory cytokines, is another key pathological feature in diabetic cognitive impairment. Chronic systemic inflammation, exacerbated by hyperglycemia and metabolic stress, leads to deleterious neuroinflammatory cascades. The combined treatment markedly attenuated neuroinflammatory markers, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), restoring a favorable neuroimmune environment. This anti-inflammatory effect is particularly significant, as it helps to dismantle the vicious cycle of inflammation-induced neurotoxicity that perpetuates cognitive decline in diabetes.
In addition to oxidative stress and neuroinflammation, neurotransmitter imbalances are critically involved in cognitive deficits. Neurotransmitters such as acetylcholine, dopamine, and gamma-aminobutyric acid (GABA) play pivotal roles in memory, learning, and executive function. Diabetic conditions disrupt their synthesis, release, and receptor sensitivity, impairing synaptic plasticity and overall neuronal communication. Remarkably, the combination therapy enhanced the levels and activity of key neurotransmitters in diabetic rats, supporting cognitive processes. This neuromodulatory capacity of purslane and metformin combination emphasizes the multifaceted neuroprotective mechanisms at play.
Metformin, beyond its classical role in lowering blood glucose through hepatic gluconeogenesis inhibition and improving insulin sensitivity, exhibits several pleiotropic effects that could benefit brain health. It modulates AMP-activated protein kinase (AMPK) pathways, which are involved in cellular energy homeostasis and neuroprotection. When paired with the antioxidant-rich purslane extract, metformin’s efficacy is amplified, targeting both metabolic and neural dysfunction. The study’s outcomes encourage the re-evaluation of metformin’s therapeutic potential as part of a combined regimen to treat diabetes-associated cognitive decline.
Further molecular investigations revealed that the combined treatment modulated signaling pathways related to oxidative stress response and inflammation, including enhanced expression of nuclear factor erythroid 2–related factor 2 (Nrf2) and suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). These transcription factors play antagonistic roles in the regulation of antioxidant defenses and inflammatory responses. The ability to simultaneously activate protective pathways while inhibiting harmful inflammatory signals underlines the sophisticated neuroprotective action of the treatment.
Histological analyses supported these biochemical findings by demonstrating reduced neuronal degeneration and gliosis in the hippocampus and cerebral cortex of treated diabetic rats. The hippocampus, a critical center for memory formation, suffers significant damage in diabetic cognitive impairment. Preservation of its structural integrity is indicative of effective neuroprotection, translating into better cognitive outcomes. This histopathological evidence complements the behavioral data, offering a robust validation of treatment efficacy at the cellular and tissue levels.
Cognitive performance was evaluated using standardized tests such as the Morris water maze and novel object recognition tasks. Rats receiving the combined treatment exhibited superior spatial memory retention and recognition performance compared to diabetic controls, indicating a reversal or attenuation of cognitive deficits. These functional outcomes are particularly promising, as they demonstrate not just biochemical but also real-world improvements in neurocognitive domains, a critical consideration for therapeutic relevance.
Importantly, the safety profile of purslane extract was corroborated within the experimental framework, revealing no adverse effects or toxicity at therapeutic doses. This is pivotal for clinical translation, as combination therapies must balance efficacy with minimal side effects. The natural origin and multifactorial benefits of purslane provide an attractive adjunct to conventional antidiabetic drugs like metformin, potentially improving patient adherence and outcomes through reduced polypharmacy burdens and enhanced biological synergy.
The implications of this study extend beyond animal models, hinting at potential clinical applications in human diabetic populations vulnerable to cognitive decline. Considering the increasing prevalence of diabetes worldwide and the substantial burden of diabetic neuropathies on healthcare systems, the development of adjunctive treatments targeting neuroprotective pathways is urgently needed. The combination of natural compounds with established pharmaceuticals could revolutionize current therapeutic paradigms.
Moreover, this research contributes to a growing body of evidence supporting an integrative approach to diabetes management, where metabolic control is harmonized with neuroprotection. Understanding the complex interplay between systemic metabolic disturbances and brain health will pave the way for future interventions that address multifactorial complications of diabetes holistically.
The publication of these findings in a high-impact pharmacology and toxicology journal underscores the scientific community’s recognition of the significance of natural product-based adjunct therapies combined with first-line drugs. As further preclinical studies are conducted and eventually clinical trials initiated, it is anticipated that this combination therapy could become part of treatment guidelines for diabetic cognitive dysfunction.
In conclusion, the novel therapeutic avenue explored by the researchers through the dual administration of purslane ethanolic extract and metformin presents an innovative, multifaceted intervention for cognitive dysfunction in diabetes. By modulating oxidative stress, neuroinflammation, and neurotransmitter dysregulation, this approach not only halts but potentially reverses neurodegenerative processes linked to diabetic pathology. This breakthrough opens exciting prospects in the quest for effective, safe, and accessible treatments to safeguard cognitive health in diabetic patients worldwide.
Subject of Research: Therapeutic effects of combined purslane ethanolic extract and metformin on cognitive dysfunction in diabetic rats, focusing on oxidative stress, neuroinflammation, and neurotransmitter regulation.
Article Title: Combined purslane ethanolic extract and metformin attenuate cognitive dysfunction in HFD/STZ-induced diabetic rats via modulation of oxidative stress, neuroinflammation, and neurotransmitters.
Article References: Bahr, N., El-Kader, A.EK.M.A., Eldin, A.E.S. et al. Combined purslane ethanolic extract and metformin attenuate cognitive dysfunction in HFD/STZ-induced diabetic rats via modulation of oxidative stress, neuroinflammation, and neurotransmitters. BMC Pharmacol Toxicol (2026). https://doi.org/10.1186/s40360-026-01128-w
Image Credits: AI Generated
